ALB and neoplasm: This underscores the specific tumor targeting capability of albumin nanoparticles and provides robust evidence supporting their suitability for high-dose administration.976 In vivo delivery of therapeutic molecules such as siRNA and miRNA face numerous challenges, including enzymatic degradation, interactions with blood components, and non-specific cellular uptake.